Analysts Anticipate Medpace Holdings Inc (MEDP) Will Post Earnings of $0.39 Per Share

Brokerages forecast that Medpace Holdings Inc (NASDAQ:MEDP) will announce $0.39 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Medpace’s earnings, with estimates ranging from $0.37 to $0.41. Medpace posted earnings per share of $0.35 in the same quarter last year, which would suggest a positive year over year growth rate of 11.4%. The company is scheduled to issue its next earnings report on Monday, February 26th.

According to Zacks, analysts expect that Medpace will report full year earnings of $1.50 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.52. For the next fiscal year, analysts forecast that the business will post earnings of $1.73 per share, with EPS estimates ranging from $1.67 to $1.84. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Medpace.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.40 EPS.

A number of equities research analysts have issued reports on the stock. BidaskClub raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Thursday, December 14th. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Wednesday, December 13th. Jefferies Group lifted their target price on shares of Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, November 1st. William Blair lowered shares of Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Finally, Robert W. Baird lifted their target price on shares of Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $36.60.

In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of Medpace stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 25.80% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Susquehanna International Group LLP boosted its stake in Medpace by 30.9% during the third quarter. Susquehanna International Group LLP now owns 9,947 shares of the company’s stock worth $317,000 after acquiring an additional 2,347 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Medpace by 173.8% during the third quarter. GSA Capital Partners LLP now owns 28,200 shares of the company’s stock worth $900,000 after acquiring an additional 17,900 shares in the last quarter. Convergence Investment Partners LLC boosted its stake in Medpace by 13.4% during the third quarter. Convergence Investment Partners LLC now owns 24,819 shares of the company’s stock worth $792,000 after acquiring an additional 2,940 shares in the last quarter. OxFORD Asset Management LLP boosted its stake in Medpace by 21.1% during the third quarter. OxFORD Asset Management LLP now owns 98,605 shares of the company’s stock worth $3,135,000 after acquiring an additional 17,161 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Medpace by 42.8% during the third quarter. Wells Fargo & Company MN now owns 10,354 shares of the company’s stock worth $330,000 after acquiring an additional 3,104 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of Medpace (NASDAQ:MEDP) traded up $0.45 during trading on Friday, reaching $38.05. 152,900 shares of the company’s stock were exchanged, compared to its average volume of 212,250. The company has a market cap of $1,410.00 and a price-to-earnings ratio of 55.14. Medpace has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Medpace Holdings Inc (MEDP) Will Post Earnings of $0.39 Per Share” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/12/analysts-anticipate-medpace-holdings-inc-medp-will-post-earnings-of-0-39-per-share.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit